TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers writing in The Lancet Healthy Longevity argue that age-related weakness and mobility loss should be understood as problems of the motor system, not muscle alone. They say muscle loss accounts for only part of declining strength, but acknowledge that proposed assessment measures have not yet been shown to improve outcomes or reduce costs.
Researchers writing in The Lancet Healthy Longevity argue that sarcopenia, the age-related decline in strength and physical function, should be understood as a problem of the whole motor system rather than muscle loss alone. The proposal could change how clinicians assess older adults with weakness, but the authors say new measures still need to be tested for their usefulness and cost.
The paper, by Lucas B. R. Orssatto and colleagues, says muscle mass explains only a modest share of the strength decline seen in older people. People with similar amounts of muscle can have different levels of strength and mobility, the authors note. They argue that signals from the brain and spinal cord, nerve function, balance and position sense also affect how effectively a person can move.
Current sarcopenia assessment has already shifted away from muscle mass alone. Measures such as grip strength, walking speed and chair stands are used because they can help identify functional decline and predict outcomes, the article says. The authors argue that the explanation for that decline has not kept pace: sarcopenia is still commonly framed as a muscle disease, with weakness treated as a consequence of muscle wasting.
The researchers propose broadening assessment while retaining strength and gait measures. Their suggested areas of attention include how quickly a person rises from a chair, steadiness during sustained effort, hand dexterity and whether walking changes while talking. They also say clinicians should examine weakness that is asymmetric, rapid or out of proportion to muscle loss, and review medicines that can blunt motor drive, including sedatives and anticholinergic drugs.
A Wider View of Mobility Decline
The proposal matters because weakness can affect everyday tasks, independence and fall risk, while a muscle-only explanation may not capture why one person struggles more than another with similar muscle loss. A broader assessment could help clinicians identify different contributors to impaired movement and tailor care to an individual’s needs.
The stakes are substantial in Australia, where the source report says there were 253,800 fall-related hospitalizations in 2024–25. It also reports that 6,722 Australians died following a fall in the prior year and estimates fall injuries cost the health system A$5.4 billion. Those figures describe the burden of falls; they do not show that adopting the proposed framework would reduce falls.
The authors also question whether research and treatment have focused too heavily on building muscle. They point to exercise improving strength and mobility even when muscle mass does not measurably change, and to disappointing gains in practical function from some approaches that increase muscle. The paper argues for more attention to outcomes such as movement and everyday ability, alongside muscle measures.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, with 2 Brush Heads and Travel Case
Theragun Mini 3rd Generation Massage Gun – Travel Essential (Black)
As an affiliate, we earn on qualifying purchases.
From Muscle Mass to Motor Function
Sarcopenia is a substantial loss of muscle, strength and physical function associated with aging. The source report says it affects up to 29% of community-dwelling older adults, with higher rates among hospital patients, people in residential elder care, and those with multiple health conditions or frailty. It is a contributor to frailty, disability and loss of independence.
Australian primary care has recently received a proposed algorithm for screening, assessment and management of poor muscle health, published earlier in 2026 in the Australian Journal of General Practice. The Lancet Healthy Longevity paper adds a broader conceptual argument: measures of strength and movement are useful, but the systems that produce movement may also need consideration.
Standing from a chair illustrates the distinction. The authors describe it as a task requiring speed and power, not simply muscle bulk. They argue that nerve signals and the recruitment of muscle fibers influence performance, and that power can decline earlier and faster with age than muscle mass. The article presents this as a reason to investigate motor function, not proof that one particular test or treatment is best.
“We propose that sarcopenia is better understood as a disease of the aging motor system.”
— Lucas B. R. Orssatto and colleagues, in The Lancet Healthy Longevity
Evidence Still Needed for Tests
The proposed approach has not yet been shown to outperform existing screening on patient outcomes or cost, according to the authors. The paper does not establish that assessing dexterity, dual-task walking or chair-rise speed will prevent falls or preserve independence. Nor does the source report identify a validated set of motor-system tests ready for routine use in primary care.
Access to clinicians with neuromuscular expertise also varies, the authors say. It remains unclear which practical measures would work reliably in ordinary clinics, how they should be combined with existing assessments, or which treatments would be most effective for different causes of weakness. The proposal is an argument for research and assessment development, not a replacement diagnostic standard.
Testing a Broader Clinical Approach
The authors call for international working groups that set sarcopenia diagnostic criteria to consider a five-point agenda. The source report does not detail all five points, but describes the broader priorities as validating practical tests, developing guidelines for a staged assessment and running trials that measure nerve as well as muscle.
For now, clinicians can continue using established strength and mobility measures while considering other possible contributors when a patient’s decline is unusual or out of proportion to muscle loss. Whether the proposed framework changes diagnostic guidance will depend on validation studies and clinical trials showing that the additional assessment improves decisions or outcomes.
Key Questions
What does sarcopenia mean?
Sarcopenia refers to age-related loss of muscle, strength and physical function. The paper argues that its assessment should also account for the wider systems involved in movement.
What is the motor system in this paper?
The authors use the term for the structures involved in producing movement, from the brain and spinal cord through nerves and their connections to muscle. They also discuss balance and position sense as relevant to mobility.
Does the paper show that new tests prevent falls?
No. The authors say the proposed measures have not been shown to outperform existing screens on outcomes or cost. The paper calls for validation and trials rather than claiming proven fall prevention.
What should clinicians assess alongside muscle strength?
The authors suggest considering chair-rise speed, steadiness, hand dexterity and changes in walking while talking, as well as reviewing certain medicines. These are proposed assessment areas; the paper does not establish them as a validated replacement for current screening.
Source: rss
